eric
02-09-2005, 05:45 PM
[Health India]: New Delhi, Feb 9 : A top pharmaceutical healthcare company Wednesday announced human clinical trials soon for its new cancer drug.
Nicholas Piramal India Ltd (NPIL) will start trials of the new chemical entity - anti-cancer molecule NP102 - by April, said Swati Piramal, the company's director for strategic alliances and communications.
"Our pre-clinical trials have been on schedule. We are still debating on the location for the human clinical trials," Piramal said on the sidelines of the Biotech India 2005 conference here.
She said anti-cancer molecule NP102 has undergone extensive pre-clinical trials in India, Germany and US.
It has been found effective in arresting the abnormal multiplication of cells in five types of cancer - prostate, lung, colon, leukaemia and breast.
Piramal said the company is focusing on new drugs and clinical trials. "We are proposing to invest $270 million over the next six years in research and development," she said.
In November last year, Nicholas Piramal started operations at a new state-of-the-art research facility in Mumbai with an investment of $20 million.
Nicholas Piramal is one of the top 20 biotech companies in the country. It has been working in alliance with state-owned and private companies on antibiotics, pain management, neuro-psychiatry and anti-diabetic segments.
--Indo-Asian News Service
Biotech giant to begin human trials for cancer drug (http://athens-olympics-2004.newkerala.com/?action=fullnews&id=70103)
Nicholas Piramal India Ltd (NPIL) will start trials of the new chemical entity - anti-cancer molecule NP102 - by April, said Swati Piramal, the company's director for strategic alliances and communications.
"Our pre-clinical trials have been on schedule. We are still debating on the location for the human clinical trials," Piramal said on the sidelines of the Biotech India 2005 conference here.
She said anti-cancer molecule NP102 has undergone extensive pre-clinical trials in India, Germany and US.
It has been found effective in arresting the abnormal multiplication of cells in five types of cancer - prostate, lung, colon, leukaemia and breast.
Piramal said the company is focusing on new drugs and clinical trials. "We are proposing to invest $270 million over the next six years in research and development," she said.
In November last year, Nicholas Piramal started operations at a new state-of-the-art research facility in Mumbai with an investment of $20 million.
Nicholas Piramal is one of the top 20 biotech companies in the country. It has been working in alliance with state-owned and private companies on antibiotics, pain management, neuro-psychiatry and anti-diabetic segments.
--Indo-Asian News Service
Biotech giant to begin human trials for cancer drug (http://athens-olympics-2004.newkerala.com/?action=fullnews&id=70103)